A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg
every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and
maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network
(NCCN) guidelines).